Although our planned assessment of mammary cancer was not possible due to early-onset neurodegeneration, the results still predict that Atg7 ablation may impair the fitness and survival of Palb2 mutant cancer cells, thereby delaying or preventing tumor development. This evidence concerns the gene ATG7 and breast cancer.